FDA has accepted for review the filing of a supplemental New Drug Application for XTANDI (enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer.
After Karen Knudsen departed from the American Cancer Society late last year, the question of where she will end up becoming the fodder for cocktail party chatter throughout oncology.
